title: [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy].
abstract: We reviewed clinical records of 4 cases with squamous cell carcinoma in anus to evaluate the clinical effectiveness of the chemoradiotherapy. The radiation therapy consisted of 40 Gy was delivered to pelvis and bilateral inguinal lesion, and perianal booster dose of 20 Gy, in fractions of 2.0 Gy per day, was given five days a week. On the first day of radiation therapy, 750 mg/m2 of 5-FU in the form of a continuous 24-hour infusion for 5 days was given. On the first day of chemotherapy, 10 mg/m2 of MMC was also given as a single bolus infusion. 5-FU and MMC were administered 4 times every 4 weeks. Three patients had T2 tumor, and one patient had T1 tumor. One patient had metastases in para-aortic and Virchow lymph node. No patients had hematogenous metastases. Grade 1 or 2 adverse effects occurred in 3 patients during chemoradiotherapy, but the completion of chemoradiotherapy was achieved in all of the 4 patients. All patients had complete response in the anal lesion after chemoradiotherapy. No patients had any sign of recurrence in anal lesion. Chemoradiotherapy was expected to be a safe and effective treatment to improve prognosis for anal squamous carcinoma.
authors.affiliation: Dept. of Surgery, Fujita Health University.
authors.forename: Harunobu
authors.initials: H
authors.lastname: Sato
authors.forename: Koutarou
authors.initials: K
authors.lastname: Maeda
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Koide
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsuoka
authors.forename: Tomohito
authors.initials: T
authors.lastname: Noro
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Honda
authors.forename: Miho
authors.initials: M
authors.lastname: Shiota
authors.forename: Tomoyoshi
authors.initials: T
authors.lastname: Endo
authors.forename: Shinji
authors.initials: S
authors.lastname: Ozeki
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Fukuda
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011829:Radiation Dosage; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D016685:Mitomycin; D005472:Fluorouracil